Determination of Cytotoxicity Intensity of Medical Devices: In Vitro Cytotoxicity Testing per ISO 10

In vitro cytotoxicity testing is the foundational screening step in the biological safety evaluation of medical devices, determining whether a device or its leachable substances can cause injury to living cells. This article explains the principles, sample types, test items, qualitative and quantitative methods, and acceptance criteria used for the determination of cytotoxicity intensity in accordance with ISO 10993-5 and the corresponding GB/T 16886.5 standard. Regulatory submissions, material screening, and change-control programs all rely on these validated methods to demonstrate biocompatibility.

Technical Overview

Cytotoxicity refers to the capacity of a material or its extractable chemical constituents to cause cell death, membrane damage, metabolic impairment, or inhibition of cell proliferation. Because nearly every category of medical device comes into direct or indirect contact with patient tissue, cytotoxicity testing is positioned by ISO 10993-1 as one of the first and most informative tests in any biological evaluation program. The determination of cytotoxicity intensity answers two questions: whether the device is cytotoxic at all, and, if so, how strong the cytotoxic effect is.

The internationally recognized methodology is defined in ISO 10993-5 (Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity), which is harmonized in China as GB/T 16886.5. Related guidance includes ASTM F813 and ASTM F895 for agar overlay and direct contact approaches. The test principle is straightforward: cultured mammalian cells, most commonly L929 mouse fibroblasts, BALB/c 3T3 cells, or V79 cells, are exposed to the test sample or an extract of it, and the resulting cellular injury is then evaluated either morphologically, using a graded reactivity scale, or quantitatively, by measuring cell viability with a colorimetric or fluorescent indicator.

The intensity of the cytotoxic response is expressed in two complementary ways:

• Qualitatively, as a reactivity grade from 0 (no reactivity) to 4 (severe reactivity), based on the extent of cell lysis, rounding, detachment, and growth inhibition observed in the zone surrounding or beneath the sample.
• Quantitatively, as a percentage of cell viability relative to a blank control, typically determined by MTT, WST-8, XTT, neutral red uptake, or resazurin reduction assays.

In vitro cytotoxicity testing is fast, sensitive, standardized, and reproducible, making it an efficient early warning tool in design verification, batch release support, and regulatory submissions handled by accredited third-party laboratories operating under ISO/IEC 17025 quality systems.

Testing Samples

Surface-Contacting Devices

Devices that contact intact skin or mucosal membranes, such as wound dressings, adhesive tapes, drainage sheets, surgical gowns and drapes, examination gloves, and transdermal electrode patches, are routinely screened for cytotoxic leachables, particularly adhesives, plasticizers, and residual monomers.

External Communicating Devices

Products such as intravenous catheters, infusion sets, syringes, extension tubing, hemodialyzers, blood oxygenators, endoscope sheaths, and respiratory circuits are evaluated because their extractable substances can enter the circulatory or respiratory pathways, where even mild cytotoxicity is clinically significant.

Implantable Devices and Biomaterials

Ancillary and Process-Related Materials

Primary packaging that contacts the device, printing inks, adhesives, sterilization carriers, process lubricants, coatings, and cleaning agent residues are also tested, since changes in these elements can introduce new cytotoxic hazards even when the device design itself is unchanged.

Testing Items

A complete cytotoxicity determination typically comprises the following test items, selected according to the physical form of the sample and the intended use of the data:

• Qualitative morphological assessment of the cell monolayer under and around the sample, graded 0 to 4 per ISO 10993-5.
• Quantitative cell viability determination by MTT tetrazolium reduction assay, the most widely applied quantitative endpoint.
• Alternative or confirmatory viability assays, including WST-8/CCK-8, XTT, neutral red uptake, resazurin (Alamar Blue) reduction, and intracellular ATP luminescence.
• Cell membrane integrity indicators, such as lactate dehydrogenase (LDH) release and trypan blue or fluorescein diacetate staining.
• Proliferation endpoints, including direct cell counting and colony-forming efficiency, for materials expected to affect cell division rather than acute survival.

The core acceptance logic is identical across the quantitative assays: if cell viability falls below 70% of the blank control, the sample is considered to have cytotoxic potential and requires further investigation.

Testing Methods

Sample Preparation per ISO 10993-12

Extracts are prepared under aseptic conditions using a polar vehicle, typically complete mammalian cell culture medium supplemented with serum, and, where a broader extraction profile is needed, an additional non-polar vehicle. Standardized surface-area-to-volume ratios are applied, for example 6 cm²/mL for materials thinner than 0.5 mm, 3 cm²/mL for 0.5 mm to 1 mm thickness, and 1.25 cm²/mL for materials thicker than 1 mm, while irregular or porous solids are extracted at approximately 0.1 g/mL. Common extraction conditions are (37 ± 1)°C for (24 ± 2) hours, with alternative regimens of (50 ± 2)°C for 72 hours, (70 ± 2)°C for 24 hours, or (121 ± 2)°C for 1 hour when justified to simulate or exaggerate clinical exposure.

Extract (Elution) Method

A near-confluent monolayer of L929 or equivalent fibroblasts is exposed to the undiluted extract and a dilution series, commonly 100%, 50%, 25%, and 12.5%, for 24 to 72 hours at 37°C in a humidified 5% CO₂ incubator. This is the most versatile and widely used approach because it accommodates virtually any device geometry, supports dose-response characterization, and lends itself directly to quantitative viability measurement.

Direct Contact Method

The test specimen is placed directly onto the cell monolayer and incubated for approximately 24 hours. The method is highly sensitive for detecting leachable toxicity from low-density materials such as gels, fabrics, and absorbent matrices, but interpretation must distinguish true chemical cytotoxicity from physical damage caused by specimen weight or sharp edges, which is why controls are essential.

Indirect Contact Methods

In the agar diffusion (agar overlay) test, cells are covered with a thin layer of nutrient agar and a supravital dye such as neutral red, and the sample is placed on the agar surface, allowing only diffusible substances to reach the cells. The filter diffusion variant places a membrane between sample and cells and is suited to evaluating low-molecular-weight toxicants. Both methods are preferred for high-density, non-absorbent materials where direct placement would mechanically traumatize the monolayer.

Quantitative MTT Assay Workflow

Following the exposure period, the medium is replaced with MTT solution and cells are incubated for approximately two hours, during which metabolically active cells reduce the yellow tetrazolium salt to purple formazan crystals. The crystals are solubilized in isopropanol or DMSO, and absorbance is read at 570 nm with a 650 nm reference. Viability is calculated as the sample absorbance divided by the blank control absorbance multiplied by 100, and results from replicate wells are evaluated statistically.

Controls, Interpretation, and Reporting

Each run includes a negative control, typically certified high-density polyethylene reference material, a positive control such as an organotin-stabilized polyurethane or a cytotoxic surfactant like Triton X-100, and a blank control consisting of extraction vehicle alone. A valid test requires the controls to behave as expected. Qualitative grades of 0 to 2 are generally accepted as non-cytotoxic, whereas grades above 2, or quantitative viability below 70%, indicate cytotoxic potential. Positive findings trigger follow-up under ISO 10993-18 chemical characterization, extractables and leachables profiling, and risk assessment per ISO 14971. The test report documents the cell line and passage number, extraction ratio and conditions, exposure duration, grading or viability data, control performance, and the final conclusion.

Applications

Cytotoxicity intensity data support a broad range of engineering and regulatory activities across the medical device lifecycle:

• Biocompatibility documentation for regulatory submissions in major jurisdictions, including FDA premarket notifications, EU MDR conformity assessment, and NMPA registration dossiers.
• Early-stage material screening and comparative selection of polymers, metals, ceramics, coatings, and adhesives during design and development.
• Change control evaluation after modification of raw materials, suppliers, manufacturing sites, surface treatments, or sterilization methods.
• Assessment of ethylene oxide residuals, cleaning agent residues, and other process-related contaminants.
• Verification of primary packaging compatibility and evaluation of drug-device and biologic-device combination products.
• Root-cause investigation and corrective action support following complaint investigations or adverse biological findings.

Accredited third-party laboratories with validated cell culture facilities and experienced study directors are the standard route for generating submission-grade cytotoxicity data, while manufacturers may maintain in-house capability for routine screening.

FAQ

Why is cytotoxicity testing usually the first biocompatibility test performed?

It is rapid, sensitive, relatively inexpensive, and capable of detecting a wide spectrum of leachable toxicants before more complex and resource-intensive studies such as sensitization or implantation tests are initiated. A strong cytotoxic result often redirects the entire evaluation strategy.

What is the pass criterion for quantitative cytotoxicity?

Per ISO 10993-5, a test sample is regarded as having a cytotoxic potential if cell viability is reduced to less than 70% of the blank control. Viability at or above 70% indicates the sample is not cytotoxic under the conditions of the test.

How are qualitative results graded?

The reactivity of the cell monolayer is graded on a scale of 0 to 4: grade 0 shows no reactivity, grade 1 slight reactivity, grade 2 mild reactivity, grade 3 moderate reactivity, and grade 4 severe reactivity. Grades 0 to 2 are generally acceptable; grades 3 and 4 indicate cytotoxicity requiring further evaluation.

Which exposure method should be selected?

The extract method is the default choice for most devices because of its versatility and quantitative capability. Direct contact suits absorbent or low-density materials, while agar diffusion and filter diffusion are preferred for dense, non-absorbent solids whose leachables can diffuse through an intervening layer.

How should extraction conditions be chosen?

Extraction should be rigorous enough to challenge the material but representative of clinical exposure. The standard 37°C for 24 hours is most common; harsher conditions such as 50°C for 72 hours or 121°C for 1 hour may be justified for implants or to simulate worst-case processing.

How long does the test take?

Once cells are expanded and extracts are prepared, the exposure and readout phases typically take about one week; the complete study, including cell culture preparation, controls, and reporting, generally ranges from two to four weeks depending on the extraction condition and any dilution series or repeat testing required.

What happens if a sample fails the test?

A confirmed positive result is not automatically a rejection of the device. The standard follow-up includes repeating the test to rule out artifacts, performing chemical characterization to identify the causative leachable, evaluating dose-response relationships, modifying materials or processes where feasible, and conducting a toxicological risk assessment to determine whether the exposure level is clinically acceptable.